Adalat® in the Asian Pacific Region

  • David T. Kelly
Conference proceedings

Table of contents

  1. Front Matter
    Pages I-XIV
  2. Ischemic Heart Disesae

    1. Front Matter
      Pages 1-1
    2. R. F. Abarquez, V. M. Sison, R. G. Sy, N. S. Abelardo, R. R. Castillo, R. D. Jara et al.
      Pages 12-25
    3. P. G. Hugenholtz
      Pages 26-33
    4. Y. Nakamura, S. Sasayama, H. Nonogi, S. Miyazaki, Y. Kihara, T. Konishi et al.
      Pages 34-44
  3. Atherosclerosis

  4. Hypertension

    1. Front Matter
      Pages 83-83
    2. M. Hiwatari, K. Abe, K. Yoshinaga, T. Saito, S. Sasou
      Pages 103-108
    3. T. Santoso, D. Ismail, A. M. Rahman, M. N. T. Wangge, H. Mansjoer, T. Sugiarti et al.
      Pages 109-118
  5. Special Topics

    1. Front Matter
      Pages 119-119
    2. Y. Hirota, G. Shimizu, K. Kaku, Y. Kita, T. Saito, K. Kawamura
      Pages 127-132
  6. Back Matter
    Pages 133-138

About these proceedings

Introduction

These are the proceedings of the third Asian Pacific Adalat Symposium. The first was held in Tokyo in 1982 and the second in Sydney in 1985. We were honoured that the late Dr. Sukaman and his colleagues were able to host this third symposium in Jakarta. This meeting was designed to contribute to and to promote international collaboration in cardiovascular research, and to help promote further knowledge and understanding about the treatment of vascular disease in the Asian Pacific area. Nifedipine was originally investigated in the mid-1960s by Prof. Fleckenstein. His first results showed this drug was a powerful calcium antagonist which altered excitation contraction. At this time, there was a rapid development of knowledge about the pathophysiology of ischaemic heart disease, and thus the important pharmacological work on calcium antagonists such as nifedipine paralleled and complimented the newer understanding of coronary physiology in man. In a short time most therapy was designed to reduce myocardial oxygen consumption and demand.

Keywords

Calcium-Antagonisten Herzinsuffizienz Hypertonie Nifedipin Pharmakologie cardiovascular hypertension

Editors and affiliations

  • David T. Kelly
    • 1
  1. 1.Hallstrom Institute of Cardiology, Royal Prince Alfred HospitalUniversity of SydneyCamperdownAustralia

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-74911-7
  • Copyright Information Springer-Verlag Berlin Heidelberg 1989
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-540-51388-9
  • Online ISBN 978-3-642-74911-7
  • About this book